Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework. | Biochem Pharmacol | 2026 | 42082122 | PubTator, text mining | PubMed |
| Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. | bioRxiv | 2026 | 42079286 | PubTator, text mining | PubMed |
| PRMT5 promotes cerebral ischemia/reperfusion-induced ferroptosis via Nrf2/SLC7A11/GPX4 signaling. | Brain Res | 2026 | 42034259 | PubTator, text mining | PubMed |
| PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer. | Mol Cancer Ther | 2026 | 42012942 | PubTator, text mining | PubMed |
| Manganese-potentiated cGAS-STING activation with ATM/PRMT5 inhibition remodels the immunosuppressive microenvironment in osteosarcoma via bone-targeted delivery. | Bioact Mater | 2026 | 42006004 | PubTator, text mining | PubMed |
| TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers. | Cancer Discov | 2026 | 42001523 | PubTator, text mining | PubMed |
| Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies. | NPJ Precis Oncol | 2026 | 42000949 | PubTator, text mining | PubMed |
| PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis. | Leukemia | 2026 | 41998301 | PubTator, text mining | PubMed |
| PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma. | Cell Death Dis | 2026 | 41986321 | PubTator, text mining | PubMed |
| Oncologic strategies and options for the management of metastatic thymic carcinoma. | Mediastinum | 2026 | 41982608 | PubTator, text mining | PubMed |
| PRMT5-mediated arginine methylation of HSP90AA1 drives esophageal squamous cell carcinoma progression. | Cancer Lett | 2026 | 41966513 | PubTator, text mining | PubMed |
| PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors. | bioRxiv | 2026 | 41959302 | PubTator, text mining | PubMed |
| Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. | Blood Cancer J | 2026 | 41951585 | PubTator, text mining | PubMed |
| PRMT5 Methylates and Stabilizes EphA2 via Inhibiting Its Ubiquitination and Degradation to Promote Nasopharyngeal Carcinoma Stem Cell Properties. | MedComm (2020) | 2026 | 41930341 | PubTator, text mining | PubMed |
| Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities. | J Biomed Sci | 2026 | 41928257 | PubTator, text mining | PubMed |
| PRMT5-mediated symmetric dimethylation of SHBs at Arg169 stabilizes SHBs and promotes angiogenesis and tumor growth. | Tumour Virus Res | 2026 | 41903748 | PubTator, text mining | PubMed |
| Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors. | Cancers (Basel) | 2026 | 41899498 | PubTator, text mining | PubMed |
| A synergistic interaction between PRMT5 and LSD1 inhibitors in AML. | Sci Adv | 2026 | 41894488 | PubTator, text mining | PubMed |
| Integrative Analysis of Post-Translational Modifications Identifies a PTM-Enriched Regulatory Core in Human Metabolic Enzymes. | Metabolites | 2026 | 41893314 | PubTator, text mining | PubMed |
| Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay. | Epigenomes | 2026 | 41892363 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=5